objeCtives: To forecast the number of advanced melanoma (AM) patients (Stage III unresectable and Stage IV) newly initiating treatment over 5 years (2014) (2015) (2016) (2017) (2018) by line of therapy and clinical/tumor characteristics including BRAF/PD-L1 mutations status and rate of brain metastases. Methods: A patient count model was developed to forecast the AM population using historical rate data ) and other population parameters including incidence rate annual percent change, stage at diagnosis, rates of disease progression and survival obtained through a comprehensive literature review and hand-search of cancer registry websites. Analysis of a cross-sectional sample (Ipsos Global Oncology Monitor) of 1,297 patients in the EU-5 was used to address any clinical data gaps. The model was validated by comparing projected 5-year prevalence rates to GLOBOCAN 2012 estimates. Results: The model-projected number (rounded to nearest 100) of incident melanoma cases for 2014 was: Germany= 23,100; UK= 18,900; France= 12,400; Italy= 12,000; Spain= 5,800. Of incident cases, 11.3%-13.0% were treatment eligible AM. Incidence rates increases of 1.7-7.8% per year were applied based on historical trends. Analysis of IPSOS data and review of the literature showed BRAF and PD-L1 prevalence rates of 45.4%-56.2% and 15.9%-16.7%, in AM patients, respectively. Literature-derived, brain metastasis prevalence ranged from 15.9-36.0% in Stage IV patients. Considering case progression, resection and adjuvant treatment rates, the forecasted number of AM patients eligible for 1 st and 2 nd line treatment in 2018 is, respectively: Germany= 3,700 and 1,700; UK= 3,100 and 1,400 France= 1,900 and 500; Italy= 1,800 and 1,000; Spain= 1,100 and 400, representing approximately 10.8-12.0% of incident cases. ConClusions: While melanoma incidence is projected to increase over the next 5 years the majority of incident cases will be diagnosed in earlier disease stages. Under these assumptions, the largest proportion of the incident melanoma population that is AM patients initiating treatment is expected to be 12% in 2018, a slight decline from 13% in 2014. (n= 39,929) . Risk factors for LRRs within five year of the primary treatment were determined using logistic regression. Risks were determined per year, conditional on not being diagnosed with recurrence in the previous year. The presence of interaction and collinearity in the nomogram was assessed, as well as the discrimination by means of the area under the ROC curve and calibration by the Hosmer-Lemeshow goodness-of-fit test in deciles. Data on primary tumours diagnosed between 2007-2008 from a selection of Dutch hospitals was used for external validation of the performance of the nomogram (n= 13,792). Results: The final model included the variables grade, size, multifocality, and nodal involvement of the primary tumour, type of surgery, and whether patients were treated with radio-, chemo-or hormone therapy. The modelling group showed an area under the ROC curve of 0.82,0. 74,0. 67,0. 70 and 0.60 respectively per subsequent year after primary treatment. The calibration was sufficient. All effects in the validation group were in the same direction, and the estimates in the validation group did not differ significantly from the modelling group. ConClusions: This validated nomogram can be used as an instrument to aid clinical decision-making and to identify patients with a high risk of breast cancer recurrence who might benefit from a more intensive follow-up after breast cancer. using electronic hospital records. Survival was assessed using the Kaplan-Meier estimator. Recurrence patterns were investigated by type of first recurrence and time-to-recurrence. A multivariate cox regression was used to analyze whether time-to-recurrence was associated with gender, age and tumor thickness. Emigrated patients (n= 10) and patients with an unknown recurrence status (n= 144) were excluded. Results: Of all 817 patients, 111 patients (13.6%) experienced disease progression (median follow-up: 5.5 years). Patients who developed a recurrence had a lower survival compared to patients who did not developed a recurrence (median OS: 9.4 years versus median has not yet been reached; 5-year survival rate: 69.9% versus 96.6%; p< 0.001). The most frequent type of first recurrence was lymphatic (36.9%), followed by distant (22.5%), local (21.6%) and intralymphatic (9.9%), respectively. The median time-to-recurrence has not yet been reached; however, in case of a recurrence, the median time-to-recurrence was 2.5 years (minimum: 0.01 years; maximum: 9.8 years). The time-to-recurrence was not statistically significantly associated with gender (HR= 0.81; p= 0.29), age (HR= 1.01; p= 0.38) and tumor thickness (HR= 1.03; p= 0.76). ConClusions: Long-term surveillance of stage IB melanomas is of utmost importance, because survival subsequent to recurrence is much lower than expected. The risk of developing a recurrence was substantial; however, the time-to-recurrence was not associated with gender, age and tumor thickness. objeCtives: The objective of this study was to evaluate both the incidence of metastatic Castrate Resistant Prostate Cancer (mCRPC) and the number of mCRPC patients who receive specific mCRPC treatments (mCRPCTT): chemotherapy and second generation Hormone Therapies (ADT manipulations were not included). Methods: This study was conducted in 8 European countries and Australia The incidence of mCRPC patients was assessed using several sources: national cancer registries, a literature review and an ad-hoc chart review where 292 oncologists, 76 onco-radiotherapists and 357 urologists reported information about 4171 prostate cancer patients. Of these, 2401 had metastatic castrate resistant disease. Patient characteristics and treatments received were assessed and reported separately by country. Results: Across all 9 countries, 76 200 new patients were diagnosed mCRPC over the past year. Of these patients, 35% (26 400 patients) went to supportive care without receiving any mCRPC TT while 65% (49 800 patients) received a 1L mCRPCTT. Prior to receiving any 1L mCRPCTT, 43% of patients had ADT manipulations during a short transitional period (median duration = 1 month). Of the 49 800 patients who received a 1L mCRPCTT, 59% (29 250) went to a 2L mCRPCTT, 15% deceased during or just after the 1L TT and 26% went on to receive supportive care only. Of the 29 250 patients who received a 2L mCRPCTT, 46% (13 500) went to a 3L mCRPCTT. ConClusions: Our methodology enabled us to assess incidence figures and the volume of mCRPC patients who receive specific mCRPCTT: over one-third of mCRPC patients did not receive any mCRPCTT. Among the 65% who received a 1L TT, 59% receive a 2L mCRPCTT. objeCtives: Explore differences/similarities in epidemiology and drug treatment of metastatic breast cancer (MBC) in EU5. Methods: All data was derived from the Kantar Health CancerMPact database, sources for which include country specific cancer registries, published scientific studies and proprietary physician surveys comprising 85 doctors seeing 9,255 patients per month. Age and gender specific incidence rates, annual stage specific progression rates and annual stage specific survival rates are used to calculate total number of surviving patients at a specific stage up to 10 years after diagnosis. Results: Prevalence of BC ranged between 41-73 per 100K population across EU-5. Among BC patients, prevalence of MBC was similar: 8% (UK, Italy) to 10% (Germany, France, Spain). Overall 62% of MBC patients were diagnosed with HER2-negative disease (56% Germany-70% France). Among these patients 35-40% had active disease and were treated with chemotherapy. Patients with triple negative disease had had fewer lines of treatment than did not triple negative. Patients who are HER2-negative generally receive between two and three lines of chemo therapy on average. Second line chemotherapy regimens varied. Capecitabine was the most common therapy (mono and combination) in all countries ranging from 36% (UK) to 40% (Germany). 2 nd and 3 rd most common therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. In third line, the most commonly used agents were capecitabine (16%-44%) and vinorelbine (18%-26%). Eribulin was used in second line (3%-6%) and third line (11%-19%) in all countries except for Spain. ConClusions: Capecitabine is the most utilized chemotherapeutic agent in the second and third lines chemotherapy in Western Europe for HER2-negative patients. A variety of other regimens, primarily monotherapies, may also be used in later lines, including vinorelbine, gemcitabine, eribulin, and docetaxel.
PCN34 a validated PrediCtioN Model aNd NoMoGraM for risK of reCurreNCe iN early breast CaNCer PatieNts

PCN30 ePideMioloGy of PatieNts with MetastatiC Castrate resistaNt Prostate CaNCer iN euroPe aNd australia
PCN31
CoMParisoN of ePideMioloGy aNd druG treatMeNt iN her2 NeGative MetastatiC breast CaNCer (MbC) iN eu5
PCN32 assoCiatioN of diabetes aNd CaNCer diaGNosis iN PriMary Care PraCtiCes iN fraNCe
Grandfils N. , Ricarte C. , Solomiac A.
IMS Health, PARIS LA DEFENSE, France
objeCtives: Several studies suggest that diabetes carries an increased risk for a number of different cancer types. The aim of this study was to investigate the incidence of 14 different cancer types in the diabetic and non-diabetic popula- objeCtives: For patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), prognosis is poor, with a median survival of one to two years, and treatment options are very limited. In a recent phase II trial (PCYCY-1104), Ibrutinib (Imbruvica™), a first-in-class oral once a day covalent Bruton's tyrosine kinase inhibitor, was associated with a median progression-free survival (PFS) of 13.9 months. After a median follow-up of 15.3 months, 63% of patients were alive. The aim of the current study was to evaluate the projected life years (LYs) and quality-adjusted LYs (QALYs) associated with ibrutinib and other treatments for R/R MCL. Methods: Patients with R/R MCL were simulated to receive treatment in a health state, survival partition model. Patients received ibrutinib, bendamustine and rituximab (BR), fludarabine, mitoxantrone, and cyclophosphamide (FMC), temsirolimus, or other comparators until death or until progression of disease, at which point they were modeled to receive a subsequent line of treatment or best supportive care. Clinical inputs for ibrutinib were informed by PCYC-1104 trial data; OS was extrapolated to estimate survival outcomes. Clinical inputs for comparators were informed by published sources identified through a systematic literature review. Utility values were informed by published studies. Outcomes were discounted by 3.5%. Results: Treatment with ibrutinib resulted in better health outcomes, incrementally increasing overall LYs by 0.92, 0.86, and 0.92 and PFS LYs by 0.87, 0.87, and 0.87 compared to BR, FMC, and temsirolimus, respectively. Ibrutinib was associated with 0.71, 0.70, and 0.72 overall incremental QALYs compared to BR, FMC, and temsirolimus, respectively. ConClusions: Compared with other therapies, Ibrutinib yielded an average incremental benefit of 0.90 LYs for R/R MCL patients, largely driven by the significant incremental improvement in duration of PFS. Currently a phase III trial is ongoing, the data from which will be used to validate the model. ). In the third-line setting, the association of lapatinib + trastuzumab has demonstrated to improve OS in 4.5 months compared with lapatinib alone (14 months vs 9.5 months; Blackwell et al, 2012) . ConClusions: The HER-2 directed therapies had an undeniable benefic impact in the overall survival of patients with HER-2 positive metastatic breast cancer. Triple combination of docetaxel, pertuzumab and trastuzumab is associated with a survival extent of more than 3.5 years, compared with a life expectancy of 1,5 years achieved 13 years ago. 
PCN40 siMulatioN Model of ibrutiNib for ChroNiC lyMPhoCytiC leuKeMia (Cll) with Prior treatMeNt
objeCtives:
The association between the disease-free interval (DFI) and survival after a locoregional recurrence (LRR) or second primary (SP) breast cancer remains uncertain. The objective of this study is to clarify this association to obtain more information on expected prognosis. Methods: Women first diagnosed with early breast cancer between 2003-2006 were selected from the Netherlands Cancer Registry. LRRs and SP tumours within five years of first diagnosis were examined. The five-year period was subsequently divided into three equal intervals. Prognostic significance of the DFI on survival after a LRR or SP tumour was determined using Kaplan-Meier estimates and multivariable Cox regression analysis. Follow-up was complete until January 1,2013. Results: A total of 36,255 women was included in the analysis. LRRs or SP tumours were diagnosed in 1,646 (4.5%) patients: 55% developed a LRR and 45% SP breast cancer. Longer DFI was strongly and independently related to an improved survival after a LRR (long versus short: HR 0.63, 95% CI 0.46-0.86; medium versus short HR 0.80, 95% CI 0.64-1.00; P for trend 0.01). Other factors related to improved survival after LRR were younger age (< 70 years) and surgical removal of the recurrence. No significant association was found between DFI and survival after SP tumours. ConClusions: This is the first study to explore the association between the DFI and survival after recurrence in a nationwide populationbased cancer registry. The DFI before a LRR is an independent prognostic factor for survival, with a longer DFI predicting better prognosis.
PCN36 loNG terM survival of PatieNts with various luNG CaNCer histoloGy iN seer betweeN 2004-2011
Schmaus K 1 , Benedict A 2 1 Evidera, San Francisco, CA, USA, 2 Evidera, Budapest, Hungary objeCtives: Overall survival (OS) data from clinical trials in oncology are often incomplete, thus modelling over the lifetime horizon requires long term extrapolation and it is a critical input to cost-effectiveness studies. Data from the Surveillance, Epidemiology, and End Results (SEER) program may provide good validation on the long term OS. The objective was to examine the parametric functions that best fit data in lung cancer (LC) of various histologies in SEER. Methods: SEER data (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) were analyzed for patients diagnosed with stage IV small cell, large cell, squamous cell carcinoma and adenocarcinoma of the lung with complete followup. Mean age was 68.03 (sd 11.67) and 55.5% were males, with varying baseline age and gender distribution by histology. Treatment status could not be established. Parametric models for OS were fitted using exponential, Gompertz, loglogistic, lognormal, and Weibull distributions. Models were fitted with and without covariates. Fits were inspected and compared graphically using survival and quantile-quantile plots, and statistically using the Akaike Information Criterion (AIC). Modelled mean life expectancy results were compared to the restricted mean life expectancy of the Kaplan-Meier estimator. Results: The lognormal distribution was found to have the best fit within the SEER population, both with and without covariates indicating that a small proportion of patients survive for a long time despite the poor general prognosis of any type of LC. Loglogistic and gamma distributions were 2 nd and 3 rd best, followed by Weibull, Gompertz and exponential, for all histologies. The last three fitted the data poorly, and underestimated mean life expectancy. ConClusions: Only small proportions of LC patients are alive at 5-8 years, nevertheless the mean OS estimates are impacted by the choice of survival function. The lognormal distribution fit best across all histologies indicating a higher propotion of patients alive than estimated with Weibull models.
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